Using a 3D human neural cell culture model, researchers showed that this hormone leads to the production of the enzyme neprilysin, which decreases the presence of amyloid beta, according to the study, which was published Sept. 8 in the journal Neuron.
The findings could reveal “a new target pathway for therapies aimed at the prevention and treatment of Alzheimer’s disease,” Rudolph Tanzi, PhD, a senior author of the study and the director of the Genetics and Aging Research Unit, said in a press release.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
